Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

NCT ID: NCT04524884

Last Updated: 2020-08-24

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-01
• Study Completion Date: 2022-09-30

Brief Summary

This study is designed to evaluate the efficacy and safety of the combination of Toripalimab and Surufatinib for Locally Advanced Thyroid Cancer.

Detailed Description

Surufatinib (HMPL-012, previously named sulfatinib) is a small-molecule inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptor 1 and colony-stimulating factor 1 receptor. A multi-center , opened, Phase II study have identified the efficacy and safety of Surufatinib in advanced medullary thyroid Carcinoma ( MTC) and iodine-refractory differentiated thyroid carcinoma (DTC).Toripalimab is a humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. In the present study, we design a single-arm, single center Phase II trial to evaluate the efficacy and safety of the combination of Surufatinib wiht Toripalimab in locally advanced differentiated thyroid cancer as neoadjuvant therapy.

Conditions

Thyroid Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort A

Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination.

Group Type: EXPERIMENTAL

Surufatinib

Intervention Type: DRUG

Surufatinib is a tablet in the form of 50mg, oral, once a day.

Toripalimab

Intervention Type: DRUG

Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Cohort B

Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive further drug reatment, if the tumor is evaluated as unresectable cases and patients have potential benefits by clinical examination.

Group Type: EXPERIMENTAL

Surufatinib

Intervention Type: DRUG

Surufatinib is a tablet in the form of 50mg, oral, once a day.

Toripalimab

Intervention Type: DRUG

Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Cohort C

Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will be removed from the study, if the tumor is evaluated as unresectable cases and patients have no potential benefits by clinical examination.

Group Type: EXPERIMENTAL

Surufatinib

Intervention Type: DRUG

Surufatinib is a tablet in the form of 50mg, oral, once a day.

Toripalimab

Intervention Type: DRUG

Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Interventions

Surufatinib

Surufatinib is a tablet in the form of 50mg, oral, once a day.

Intervention Type: DRUG

Toripalimab

Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Intervention Type: DRUG

Other Intervention Names

HMPL-012; JS001

Eligibility Criteria

Inclusion Criteria

1. The patient volunteered to participate in the study and signed an informed consent form and shows good compliance;

2. Age ≥18 years, male or female;

3. Pathologically diagnosed locally advanced differentiated thyroid cancer, including papillary thyroid cancer and follicular thyroid cancer;

4. Diagnosis of locally advanced disease should meet at least one of the criteria:1)Unresectable locally advanced lesion; 2)Difficult to achieve R0/R1 resection during preoperative assessment; 3)AJCC T4 stage: Primary tumor with invasion or adhesion of at least one of the following structures / organs, including: trachea, esophagus, common carotid artery, larynx, anterior vertebral fascia, brachial plexus;

5. Have at least one measurable lesion (RECIST 1.1);

6. Eastern Cooperative Oncology Group (ECOG) score 0-2;

7. Expected survival time ≥ 12 weeks;

8. If the patient presents with distant metastasis, the value of local treatment should be assessed by the investigator;

9. The patient volunteered to receive tumor biopsy/surgery during rull-in and rull-out periods.

10. The main organ functions meet the following criteria within 7 days before treatment:1)Standard blood test (without blood transfusion within 14 days):Hemoglobin (HB) ≥90g / L; Absolute neutrophil value (ANC) ≥ 1.5 × 109 / L; Platelet (PLT) ≥80 × 109 / L; 2)Biochemical inspection must meet the following standards: Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN, if with liver metastases, ALT and AST ≤ 5 ULN; Serum creatinine (Cr) ≤ 1.5 ULN or creatinine clearance (CCr)>50ml / min; 3)International normalized ratio (INR) ≤2.3 or prothrombin time (PT) prolongs less than 6 seconds; 4)Urine routine indicates urinary protein <++, and the 24-hour urine protein quantification is less than 1.0 g.

11. Women of childbearing age should agree to use contraceptives during the study; negative serum or urine pregnancy tests within 14 days before study enrollment.

Exclusion Criteria

1. History of a second malignancy during the past 5 years before inclusion in the study or during participation in the study, with the exception of a dermal basal cell or squamous cell carcinoma or cervical carcinoma in situ, if these were curatively treated;

2. Use any anti-tumor treatment within 4 weeks (28 days) prior to the start of the study treatment, except for TSH suppression treatment;

3. Previously used any immune checkpoint inhibitors, including but not limited to pembrolizumab, nivolumab, camrelizumab, sintilimab and etc;

4. With other uncontrolled cardiac symptoms or disease;

5. Patients whose blood pressure is still unsatisfactory with a blood pressure medication (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg) or a history of hypertensive encephalopathy or hypertensive crisis;

6. Those who have multiple factors (such as inability to swallow) that affect oral medication;

7. Patients with a gastrointestinal bleeding tendency including 1)Active peptic ulcer; 2)Fecal occult blood ≥ ++; 3)A history of hematemesis or melena within 3 months;

8. Coagulation disorder, such as INR greater than 1.5, or activated partial thromboplastin time (APTT) greater than 1.5 * ULN;

9. Significant hemoptysis within 2 months before screening, or the daily volume of hemoptysis reached half a teaspoon (2.5ml) or more;

10. Patients whose imaging showed that the tumor had invaded the important blood vessels or the researchers judged that the tumor was likely to invade important blood vessels during the subsequent study period and caused fatal bleeding;

11. Arterial / venous thrombosis events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis and pulmonary embolism within 6 months;

12. Patients suffering from interstitial pneumonia or ILD, or with a history of interstitial pneumonia or ILD requiring hormone therapy, or with other pulmonary fibrosis，organic pneumonia(e.g., obliterative bronchiolitis), pneumoconiosis, drug-induced pneumonia and idiopathic pneumonia that may interfere with the diagnosis and management of immune-related pulmonary toxicity; or patients with CT image indicating active pneumonia or severely impaired pulmonary function during screening. Radiation pneumonia is acceptable in the radiation field. Patients with active tuberculosis will be excluded;

13. Active autoimmune disease or history of autoimmune disease with recurrence potential (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis): Patients with skin diseases that do not require systemic treatment such as vitiligo, psoriasis, hair loss, controlled type I diabetes receiving insulin therapy; childhood asthma that is completely relieved, or those who do not need any intervention in adulthood can be included; Patients with asthma who undergo medical intervention such as bronchiectasis, cannot be included;

14. Use immunosuppressive agents or systemic hormone therapy within preceding 14 days before the study starts to achieve the purpose of immunosuppression (dose>10mg/day prednisone or hormones with equivalent effects);

15. Patients who received strong CYP3A4/CYP2C19 inducer including rifampin (and its analogs) and hypericum perforatum or strong CYP3A4/CYP2C19 inhibitor within preceding 14 days;

16. Patients who have a history of severe allergies to any monoclonal antibody or anti-angiogenic targeted drugs;

17. Patients who have severe uncontrolled infection during study screening;

18. Patients who are pregnant or lactating;

19. Patients who refuse to receive tumor biopsy during rule-in and rule-out period;

20. Other reasons according to the investigator's judgement.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fudan University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Qing-Hai Ji, MD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Yu-Long Wang, MD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

270 Dongan Road, Fudan University Shanghai Cancer Center

Shanghai, , China

Countries

China

Central Contacts

Yu-Long Wang, MD

Role: CONTACT

yulongwang@fudan.edu.cn

+86-18017317225

Qing-Hai Ji, MD

Role: CONTACT

headneck@126.com

Facility Contacts

Yu-Long Wang

Role: primary

yulongwang@fudan.edu.cn

+86-18017317225

Qing-Hai Ji

Role: backup

headneck@126.com

Other Identifiers

Thca-NEO-ST

Identifier Type: -

Identifier Source: org_study_id